Expert panel discussion – accelerating precision medicine with low-cost whole-genome sequencing

Next-generation sequencing (NGS) will have a dramatic impact on healthcare in the next decade. But what are the real benefits of this trend for patients, healthcare systems, and other stakeholders?

Learn more in this article, which summarizes a roundtable discussion between a panel of experts moderated by Robert Green, a medical geneticist and a physician-researcher at Mass General Brigham, the Broad Institute, Ariadne Labs, and Harvard Medical School.

The expert panel:

  • Mark Gardner, Senior Vice President of Molecular Genomics and Oncology, Quest Diagnostics
  • Alisa Gaskell, Director of the Precision Diagnostics Laboratory and Scientific Director, Children’s Colorado Precision Medicine Institute
  • Niall Lennon, Senior Director of Translational Genomics, Broad Institute of MIT and Harvard and CSO and Chair of the Board of Managers of Broad’s Clinical Testing Laboratory
  • Aleksandar Rajkovic, Chief Genomics Officer, Professor of Pathology, Medical Director, and Chief of the Center for Genetic and Genomic Medicine, University of California, San Francisco Health System
  • Sean Hofherr, Chief Operating Officer and Clinical Director, Fabric Genomics
  • Ryan Taft, Vice President of Scientific Research, Illumina

Expert panel discussion – accelerating precision medicine with low-cost whole-genome sequencing

Image Credit: Illumina, Inc

About Illumina, Inc

At Illumina, our goal is to apply innovative technologies to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. It is mission critical for us to deliver innovative, flexible, and scalable solutions to meet the needs of our customers. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and providing the highest level of quality, we strive to meet this challenge. Illumina's innovative sequencing and array technologies are fueling groundbreaking advancements in life science research, translational and consumer genomics, and molecular diagnostics.


Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.Net which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.

Last updated: Apr 19, 2024 at 8:39 AM

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Illumina, Inc.. (2024, April 19). Expert panel discussion – accelerating precision medicine with low-cost whole-genome sequencing. News-Medical. Retrieved on October 31, 2024 from https://www.news-medical.net/whitepaper/20230907/Expert-panel-discussion-accelerating-precision-medicine-with-low-cost-whole-genome-sequencing.aspx.

  • MLA

    Illumina, Inc.. "Expert panel discussion – accelerating precision medicine with low-cost whole-genome sequencing". News-Medical. 31 October 2024. <https://www.news-medical.net/whitepaper/20230907/Expert-panel-discussion-accelerating-precision-medicine-with-low-cost-whole-genome-sequencing.aspx>.

  • Chicago

    Illumina, Inc.. "Expert panel discussion – accelerating precision medicine with low-cost whole-genome sequencing". News-Medical. https://www.news-medical.net/whitepaper/20230907/Expert-panel-discussion-accelerating-precision-medicine-with-low-cost-whole-genome-sequencing.aspx. (accessed October 31, 2024).

  • Harvard

    Illumina, Inc.. 2024. Expert panel discussion – accelerating precision medicine with low-cost whole-genome sequencing. News-Medical, viewed 31 October 2024, https://www.news-medical.net/whitepaper/20230907/Expert-panel-discussion-accelerating-precision-medicine-with-low-cost-whole-genome-sequencing.aspx.

Other White Papers by this Supplier

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.